Department of Interventional Treatment, Third Hospital of Qinhuangdao, No.222 Jianguo Road, Qinhuangdao, Hebei Province, China.
Department of Interventional Treatment, Third Hospital of Qinhuangdao, No.222 Jianguo Road, Qinhuangdao, Hebei Province, China.
Arab J Gastroenterol. 2024 May;25(2):176-181. doi: 10.1016/j.ajg.2024.01.012. Epub 2024 Feb 21.
Drug-eluting bead transarterial chemoembolization (DEB-TACE) causes serious complications, including liver abscess and biloma formation. This study aimed to investigate the frequency and risk factors of liver abscess and biloma formation after dug-eluting bead transarterial chemoembolization for unresectable intrahepatic cholangiocarcinoma (ICC).
152 unresectable ICC patients received 241 DEB-TACE procedures from February 2018 to November 2022 were studied retrospectively. Patients were evaluated for the presence of liver abscess and biloma formation after DEB-TACE. The medical records, including baseline demographic data, preoperative imaging data, DEB-TACE details, and postoperative management, were reviewed to search for risk factors of liver abscess and biloma formation.
Liver abscesses developed in 11 cases, with an incidence rate of 7.2 % (11/152) per patient and 4.6 % (11/241) per procedure. In the 11 patients with abscesses, the incidence of biloma formation was 36.4 % (n = 4). The binary logistic regression analysis showed that diabetes mellitus (OR 7.967, 95 % CI 1.491-42.571, p = 0.015), bilioenterostomy or biliary stent implantation (OR 18.716, 95 % CI 1.006-348.049, p = 0.049) and grade 1 arterial occlusion (OR 9.712, 95 % CI 1.054-89.484, p = 0.045) were independent risk factors for liver abscess and biloma formation.
Liver abscesses and biloma formation induced by DEB-TACE are associated with various factors. Diabetes mellitus, bilioenterostomy or biliary stent implantation, and grade 1 artery occlusion were all associated with liver abscess and biloma formation after DEB-TACE for unresectable ICC. In patients with these risk factors, the DEB-TACE procedure should be finely designed and manipulated with more caution.
载药微球动脉化疗栓塞术(DEB-TACE)会引起严重的并发症,包括肝脓肿和胆汁瘤形成。本研究旨在探讨不可切除的肝内胆管细胞癌(ICC)患者接受载药微球动脉化疗栓塞术后肝脓肿和胆汁瘤形成的频率和危险因素。
回顾性分析 2018 年 2 月至 2022 年 11 月期间 152 例不可切除 ICC 患者接受的 241 例 DEB-TACE 治疗。对 DEB-TACE 后患者肝脓肿和胆汁瘤形成情况进行评估。分析患者的病历资料,包括基线人口统计学数据、术前影像学资料、DEB-TACE 细节和术后管理,以寻找肝脓肿和胆汁瘤形成的危险因素。
11 例患者发生肝脓肿,发生率为 7.2%(11/152),11 例患者发生 4.6%(11/241)。在 11 例脓肿患者中,胆汁瘤形成的发生率为 36.4%(n=4)。二项逻辑回归分析显示,糖尿病(OR 7.967,95%CI 1.491-42.571,p=0.015)、胆肠吻合术或胆道支架植入术(OR 18.716,95%CI 1.006-348.049,p=0.049)和 1 级动脉闭塞(OR 9.712,95%CI 1.054-89.484,p=0.045)是肝脓肿和胆汁瘤形成的独立危险因素。
DEB-TACE 引起的肝脓肿和胆汁瘤形成与多种因素有关。糖尿病、胆肠吻合术或胆道支架植入术以及 1 级动脉闭塞均与不可切除 ICC 患者接受 DEB-TACE 后肝脓肿和胆汁瘤形成有关。对于具有这些危险因素的患者,应精心设计 DEB-TACE 手术,并更加谨慎地操作。